Sales & Marketing News | pharmaphorum

News

US court rejects J&J's talc bankruptcy deal

Shares in Johnson & Johnson have come under pressure amid reports that an appeals court in the US has rejected the bankruptcy petition filed by a new company it formed

News

EMA reviewing Novartis' Adakveo after phase 3 miss

The EMA's human medicines committee has started a review of Novartis' sickle cell disease (SCD) therapy Adakveo, shortly after the company reported that it failed to show efficacy in a phas

News

J&J copay lawsuit against drug benefit firm gets green light

Johnson & Johnson has been cleared to continue a lawsuit filed last year against drug benefit programme SaveOnSP, which claims it defrauded a payment assistance programme for patients o

News

FDA pulls AZ's Evusheld for COVID, citing lack of efficacy

AstraZeneca's revenue boost from COVID-19 therapy Evusheld looks set to be curbed early, as the FDA withdraws authorisation for the antibody on the grounds that it is ineffective against mo

News

EU clears Enhertu for HER2-low breast cancer

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be

News

Hilversum, The Netherlands - April 03, 2014. Image of a touch screen Android phone with social media apps.

ABPI code updated with first social media guidance

Guidance on the way pharma companies communicate about prescription medicines has been updated in the UK to cover use of social media channels for the first time.

US court rejects J&J's talc bankruptcy deal

EMA reviewing Novartis' Adakveo after phase 3 miss

J&J copay lawsuit against drug benefit firm gets green light

FDA pulls AZ's Evusheld for COVID, citing lack of efficacy

EU clears Enhertu for HER2-low breast cancer

ABPI code updated with first social media guidance

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks